Mesenchymal stem cells support hepatocyte function in engineered liver grafts

Yoshie Kadota, Hiroshi Yagi, Kenta Inomata, Kentaro Matsubara, Taizo Hibi, Yuta Abe, Minoru Kitago, Masahiro Shinoda, Hideaki Obara, Osamu Itano, Yuukou Kitagawa

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Recent studies suggest that organ decellularization is a promising approach to facilitate the clinical application of regenerative therapy by providing a platform for organ engineering. This unique strategy uses native matrices to act as a reservoir for the functional cells which may show therapeutic potential when implanted into the body. Appropriate cell sources for artificial livers have been debated for some time. The desired cell type in artificial livers is primary hepatocytes, but in addition, other supportive cells may facilitate this stem cell technology. In this context, the use of mesenchymal stem cells (MSC ) is an option meeting the criteria for therapeutic organ engineering. Ideally, supportive cells are required to (1) reduce the hepatic cell mass needed in an engineered liver by enhancing hepatocyte function, (2) modulate hepatic regeneration in a paracrine fashion or by direct contact, and (3) enhance the preservability of parenchymal cells during storage. Here, we describe enhanced hepatic function achieved using a strategy of sequential infusion of cells and illustrate the advantages of co-cultivating bone marrow-derived MSC s with primary hepatocytes in the engineered whole-liver scaffold. These co-recellularized liver scaffolds colonized by MSC s and hepatocytes were transplanted into live animals. After blood flow was established, we show that expression of adhesion molecules and proangiogenic factors was upregulated in the graft.

Original languageEnglish
Pages (from-to)268-277
Number of pages10
JournalOrganogenesis
Volume10
Issue number2
DOIs
Publication statusPublished - 2014 Apr 1

Fingerprint

Stem cells
Mesenchymal Stromal Cells
Grafts
Liver
Hepatocytes
Transplants
Scaffolds (biology)
Artificial Liver
Bone
Animals
Blood
Adhesion
Regeneration
Molecules
Stem Cells
Therapeutics
Bone Marrow
Technology

Keywords

  • Cell transplantation
  • Organ transplantation
  • Regenerative medicine
  • Scaffold matrix
  • Stem cell
  • Tissue engineering

ASJC Scopus subject areas

  • Developmental Biology
  • Embryology
  • Transplantation
  • Biomedical Engineering

Cite this

Mesenchymal stem cells support hepatocyte function in engineered liver grafts. / Kadota, Yoshie; Yagi, Hiroshi; Inomata, Kenta; Matsubara, Kentaro; Hibi, Taizo; Abe, Yuta; Kitago, Minoru; Shinoda, Masahiro; Obara, Hideaki; Itano, Osamu; Kitagawa, Yuukou.

In: Organogenesis, Vol. 10, No. 2, 01.04.2014, p. 268-277.

Research output: Contribution to journalArticle

@article{3c778790148b4eda93ada2b0af45d11f,
title = "Mesenchymal stem cells support hepatocyte function in engineered liver grafts",
abstract = "Recent studies suggest that organ decellularization is a promising approach to facilitate the clinical application of regenerative therapy by providing a platform for organ engineering. This unique strategy uses native matrices to act as a reservoir for the functional cells which may show therapeutic potential when implanted into the body. Appropriate cell sources for artificial livers have been debated for some time. The desired cell type in artificial livers is primary hepatocytes, but in addition, other supportive cells may facilitate this stem cell technology. In this context, the use of mesenchymal stem cells (MSC ) is an option meeting the criteria for therapeutic organ engineering. Ideally, supportive cells are required to (1) reduce the hepatic cell mass needed in an engineered liver by enhancing hepatocyte function, (2) modulate hepatic regeneration in a paracrine fashion or by direct contact, and (3) enhance the preservability of parenchymal cells during storage. Here, we describe enhanced hepatic function achieved using a strategy of sequential infusion of cells and illustrate the advantages of co-cultivating bone marrow-derived MSC s with primary hepatocytes in the engineered whole-liver scaffold. These co-recellularized liver scaffolds colonized by MSC s and hepatocytes were transplanted into live animals. After blood flow was established, we show that expression of adhesion molecules and proangiogenic factors was upregulated in the graft.",
keywords = "Cell transplantation, Organ transplantation, Regenerative medicine, Scaffold matrix, Stem cell, Tissue engineering",
author = "Yoshie Kadota and Hiroshi Yagi and Kenta Inomata and Kentaro Matsubara and Taizo Hibi and Yuta Abe and Minoru Kitago and Masahiro Shinoda and Hideaki Obara and Osamu Itano and Yuukou Kitagawa",
year = "2014",
month = "4",
day = "1",
doi = "10.4161/org.27879",
language = "English",
volume = "10",
pages = "268--277",
journal = "Organogenesis",
issn = "1547-6278",
publisher = "Landes Bioscience",
number = "2",

}

TY - JOUR

T1 - Mesenchymal stem cells support hepatocyte function in engineered liver grafts

AU - Kadota, Yoshie

AU - Yagi, Hiroshi

AU - Inomata, Kenta

AU - Matsubara, Kentaro

AU - Hibi, Taizo

AU - Abe, Yuta

AU - Kitago, Minoru

AU - Shinoda, Masahiro

AU - Obara, Hideaki

AU - Itano, Osamu

AU - Kitagawa, Yuukou

PY - 2014/4/1

Y1 - 2014/4/1

N2 - Recent studies suggest that organ decellularization is a promising approach to facilitate the clinical application of regenerative therapy by providing a platform for organ engineering. This unique strategy uses native matrices to act as a reservoir for the functional cells which may show therapeutic potential when implanted into the body. Appropriate cell sources for artificial livers have been debated for some time. The desired cell type in artificial livers is primary hepatocytes, but in addition, other supportive cells may facilitate this stem cell technology. In this context, the use of mesenchymal stem cells (MSC ) is an option meeting the criteria for therapeutic organ engineering. Ideally, supportive cells are required to (1) reduce the hepatic cell mass needed in an engineered liver by enhancing hepatocyte function, (2) modulate hepatic regeneration in a paracrine fashion or by direct contact, and (3) enhance the preservability of parenchymal cells during storage. Here, we describe enhanced hepatic function achieved using a strategy of sequential infusion of cells and illustrate the advantages of co-cultivating bone marrow-derived MSC s with primary hepatocytes in the engineered whole-liver scaffold. These co-recellularized liver scaffolds colonized by MSC s and hepatocytes were transplanted into live animals. After blood flow was established, we show that expression of adhesion molecules and proangiogenic factors was upregulated in the graft.

AB - Recent studies suggest that organ decellularization is a promising approach to facilitate the clinical application of regenerative therapy by providing a platform for organ engineering. This unique strategy uses native matrices to act as a reservoir for the functional cells which may show therapeutic potential when implanted into the body. Appropriate cell sources for artificial livers have been debated for some time. The desired cell type in artificial livers is primary hepatocytes, but in addition, other supportive cells may facilitate this stem cell technology. In this context, the use of mesenchymal stem cells (MSC ) is an option meeting the criteria for therapeutic organ engineering. Ideally, supportive cells are required to (1) reduce the hepatic cell mass needed in an engineered liver by enhancing hepatocyte function, (2) modulate hepatic regeneration in a paracrine fashion or by direct contact, and (3) enhance the preservability of parenchymal cells during storage. Here, we describe enhanced hepatic function achieved using a strategy of sequential infusion of cells and illustrate the advantages of co-cultivating bone marrow-derived MSC s with primary hepatocytes in the engineered whole-liver scaffold. These co-recellularized liver scaffolds colonized by MSC s and hepatocytes were transplanted into live animals. After blood flow was established, we show that expression of adhesion molecules and proangiogenic factors was upregulated in the graft.

KW - Cell transplantation

KW - Organ transplantation

KW - Regenerative medicine

KW - Scaffold matrix

KW - Stem cell

KW - Tissue engineering

UR - http://www.scopus.com/inward/record.url?scp=84907509516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907509516&partnerID=8YFLogxK

U2 - 10.4161/org.27879

DO - 10.4161/org.27879

M3 - Article

VL - 10

SP - 268

EP - 277

JO - Organogenesis

JF - Organogenesis

SN - 1547-6278

IS - 2

ER -